NDUFS1 is the largest catalytic core subunit of mitochondrial Complex I (NADH:ubiquinone oxidoreductase), the major entry point for electrons from NADH into the respiratory chain. In neurons, Complex I sits at the intersection of ATP generation, redox balance, and mitochondrial stress signaling, so NDUFS1 dysfunction can amplify selective vulnerability in high-demand regions such as substantia nigra and cortical association networks. Pathogenic variants in NDUFS1 are a recognized cause of severe mitochondrial disease phenotypes, often presenting with early encephalopathy, lactic acidosis, and Leigh-spectrum neurodegeneration.
NDUFS1 belongs to the matrix arm of Complex I and contributes to the proximal electron-transfer module that accepts electrons from NADH and transmits them through iron-sulfur centers toward ubiquinone reduction.[1][2] Structural studies of mammalian Complex I indicate that NDUFS1 helps stabilize the catalytic scaffold connecting N-module redox chemistry to long-range conformational coupling across the membrane arm.[1:1][3]
Functionally, this means NDUFS1 is not just a passive structural element. It modulates the efficiency and fidelity of electron transfer and can influence how much electron leak is diverted into superoxide production under stress states.[2:1][4] In the CNS, where sustained oxidative phosphorylation is required for synaptic transmission and axonal transport, even modest destabilization of this step can trigger energetic failure and secondary inflammatory signaling.[5][6]
NDUFS1-linked dysfunction converges on several pathways that recur across neurodegenerative disorders:
These mechanisms are relevant to Parkinson's disease, Alzheimer's disease, and atypical parkinsonian syndromes where mitochondrial stress appears upstream of overt neuronal loss in at least a subset of patients.[2:4][5:3][4:2]
Biallelic NDUFS1 pathogenic variants are classically associated with infantile/early-childhood mitochondrial disease, often including developmental regression, seizures, hypotonia, and Leigh-like basal ganglia/brainstem lesions.[9][10] Phenotypic severity varies by residual complex assembly and enzyme activity, but severe presentations typically reflect major impairment of respiratory chain throughput.[9:1][10:1]
Although monogenic NDUFS1 disease is rare compared with common sporadic neurodegeneration, it provides an instructive human model of how chronic Complex I failure can drive network-level CNS degeneration.[5:4][9:2] This translational bridge is relevant when evaluating mitochondrial-support interventions in broader neurodegenerative cohorts.
For NDUFS1-related biology, useful translational readouts include:
In treatment-development settings, combining molecular markers (complex activity, redox metrics) with clinical outcomes is important because compensatory pathways can mask early disease kinetics.[2:5][4:3]
No approved therapy directly restores NDUFS1 function in humans. Current management remains largely supportive and syndrome-oriented. Mechanistically, strategies under investigation across Complex I disorders and broader neurodegeneration include:
For severe inherited Complex I deficiency, future directions include genotype-specific molecular correction, but major delivery and safety hurdles remain for CNS-targeted therapy.[10:4][3:1]
Key open questions for NDUFS1-focused work in neurodegeneration:
Addressing these questions could improve mechanistic patient selection and reduce false-negative outcomes in mitochondrial-targeted interventions.[5:7][4:4][11:2]
Fiedorczuk K, Sazanov LA. Mammalian mitochondrial complex I structure and disease-causing mutations. Trends Cell Biology. 2018. ↩︎ ↩︎
Koopman WJH, Willems PHGM, Smeitink JAM. Monogenic mitochondrial disorders. Biochimica et Biophysica Acta. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kampjut D, Sazanov LA. Structure of respiratory complex I. Annual Review of Biochemistry. 2020. ↩︎ ↩︎
Vinogradov AD. Catalytic properties of the mitochondrial NADH-ubiquinone oxidoreductase. Biochimica et Biophysica Acta. 2008. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Schapira AHV. [Mitochondrial diseases](https://doi.org/10.1016/S1474-4422(12). Lancet Neurology. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics. 2012. ↩︎ ↩︎ ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015. ↩︎
Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease. Journal of Neurochemistry. 2012. ↩︎
Smeitink JAM, van den Heuvel LP, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nature Reviews Genetics. 2001. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Lake NJ, Compton AG, Rahman S, Thorburn DR. [Leigh syndrome: one disorder, more than 75 monogenic causes](https://doi.org/10.1016/S1474-4422(15). Lancet Neurology. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Beal MF. Mitochondria and neurodegeneration. Neuron. 2005. ↩︎ ↩︎ ↩︎
Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metabolism. 2019. ↩︎